Pfizer: No purchase recommendation for the BioNTech partner

The corona vaccine developed by BioNTech and Pfizer shows, according to the latest reports, an effectiveness of 95 percent. So far, the partners have spoken of more than 90 percent. In the group of test persons who are over 65 years old and thus belong to the high-risk group, the effectiveness is more than 94 percent.

According to the company, the existing safety data meets the requirements of the US authorities for an emergency approval. A corresponding application should be made within a few days. By the end of the year, 50 million doses of the vaccine should be available. 1.3 billion cans could be produced in 2021. That corresponds to 650 million vaccinations.

The DZ Bank analysts praise the vaccine’s excellent effectiveness and astonishingly good safety profile. According to Pfizer, there should be no problems with the complex cold chain involved in this vaccine. The cans must be transported and stored at -70 degrees.

The experts confirm the hold recommendation for Pfizer shares. The price target increases from $ 37.92 to $ 40.00.

For 2020, the analysts expect earnings per share of $ 2.92 (old: $ 2.77). The forecast for 2021 is raised from $ 2.99 to $ 3.15.

Related Articles

Back to top button